IN8BIO
DEAD

Serial Number

90099348

Owner

Incysus Therapeutics, Inc.

Attorney

Mark Jansen

Filing Date

Aug 7, 2020

Add to watchlist:

No watchlists yet
View on USPTO

IN8BIO Trademark

Serial Number: 90099348

IN8BIO is a trademark filed by Incysus Therapeutics, Inc. on August 7, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Incysus Therapeutics, Inc. (4 trademarks)

79 Madison Avenue
New York, NY 10016

Entity Type: 03

In8bio, Inc. (6 trademarks)

New York, NY 10118

Entity Type: 03

Trademark Details

Filing Date

August 7, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations, namely, oncological preparations; Reagent, diagnostic and therapeutic preparations for medical use in oncology; Targeted medical preparations for use in oncology; Pharmaceutical preparations for use in the treatment of cancer and tumors; Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; Pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; Medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; Pharmaceutical and biological preparations comprised of modified T cells used for multiple modes of treatment against tumor resistance and immunosuppression

Development of diagnostic medical measuring and testing methods in the field of cancer therapy and treatment

Research, development, and evaluation of new products; Pharmaceutical, medicine, and vaccine research and development services; Technical research in the field of pharmaceutical studies; Laboratory analysis and research into new drugs and pharmaceutical products; Development of scientific measuring and testing methods in the field of oncology; Design, development, research, and conducting clinical trials for others in connection with drugs, pharmaceuticals, and cellular therapies for the treatment and/or prevention of cancer; Research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; Providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; Scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 13, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 13, 2021 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
May 24, 2021 GNFN
FINAL REFUSAL E-MAILED
May 24, 2021 GNFR
FINAL REFUSAL WRITTEN
May 24, 2021 CNFR
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Apr 29, 2021 ASGN
TEAS VOLUNTARY AMENDMENT RECEIVED
Apr 28, 2021 PARI
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 21, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 20, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 20, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 20, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 20, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 8, 2020 NWOS
NEW APPLICATION ENTERED
Aug 11, 2020 NWAP